CClinicalTrials.gg
RecruitingNCT06027996Updated Dec 8, 2025

Melodi Matrix™ in Breast Reconstruction

An interventional study of Absorbable Antibacterial Matrix in Breast Reconstruction, sponsored by Melodi Health, Inc.. Recruiting at 10 sites in United States. Open to female participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2025-12-08.

Sponsored by Melodi Health, Inc. · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 1 month later.
Phase
Not applicable
Study type
Interventional
Enrollment
702
Allocation
Randomized
Ages
22 Years and older
Sex
Female
01

Study summary

Prospective, multicenter, randomized, controlled trial evaluating the safety and effectiveness of an absorbable antibacterial matrix device in two stage prepectoral alloplastic breast reconstruction.

02

Conditions studied

  • Breast Reconstruction
03

In context

Lead sponsor

This is the only study on the registry with Melodi Health, Inc. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Female.
  • Age 22 or older at the time of enrollment.
  • Is scheduled to undergo unilateral or bilateral mastectomy (including prophylactic) with immediate two-stage post-mastectomy alloplastic prepectoral breast reconstruction.
  • Is able to and willing to comply with the study requirements and providing informed consent.

Exclusion criteria

Exclusion Criteria:

  • Has prior history of neoadjuvant radiotherapy.
  • Has had prior history of failed tissue expansion or breast implantation at the intended reconstruction site.
  • Has an active abscess or infection requiring antibiotics anywhere in their body within 30 days.
  • Has a Body Mass Index (BMI) \< 14 or > 40.
  • Is pregnant or is nursing; or plans to become pregnant during the course of the study.
  • Has any connective tissue/autoimmune disorder or rheumatoid disease.
  • Has known allergies to study device materials.
  • Is participating in another interventional research study that may interfere with study endpoints.
  • Has limited life expectancy or co-morbid conditions, social/psychological problems, or cognitive impairments that precludes participation.
  • Has a medical condition or is taking medications that would result in elevated risk and/or affect the validity of the study.
  • Intraoperative assessment demonstrates unfavorable conditions (i.e., poor mastectomy skin flap thickness or viability) for immediate, two-stage post-mastectomy alloplastic prepectoral reconstruction in any breast.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
702 participants (estimated)

Study arms

  • Experimental
    Treatment

    Tissue expander implantation with the Melodi Matrix

    Device: Absorbable Antibacterial Matrix

  • No intervention
    Control

    Tissue expander implantation without a matrix

Interventions

  • DeviceAbsorbable Antibacterial Matrix

    Soft tissue support coated with antibiotics

    Also known as: Melodi Matrix™

06

What researchers measure

Primary outcomes

  1. Complications of Breast Reconstruction

    Key local complications

    Time frame: 6 months

07

Study locations

10 of 10 sites recruiting
  • Stanford University
    Palo Alto, California 94304, United States
    Recruiting
  • University of Michigan Health
    Ann Arbor, Michigan 48109, United States
    Recruiting
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
    Recruiting
  • Northwell Health
    Staten Island, New York 10305, United States
    Recruiting
  • The Ohio State University
    Columbus, Ohio 43212, United States
    Recruiting
  • UPMC
    Pittsburgh, Pennsylvania 15213, United States
    Recruiting
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
    Recruiting
  • Monument Health
    Rapid City, South Dakota 57701, United States
    Recruiting
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
    Recruiting
  • University of Utah
    Salt Lake City, Utah 84112, United States
    • Martin Carricaburu · Contact · 801-581-3363
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06027996
Lead sponsor
Melodi Health, Inc.
Responsible party
Sponsor
First posted
Sep 7, 2023
Start date
Aug 9, 2024
Primary completion
Dec 2027 (estimated)
Completion
Jun 2028 (estimated)
Last update
Dec 8, 2025

Study contacts

Michele Hilmer
Contact
michele.hilmer@melodihealth.com
210-279-0194

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion